Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 19/20 | 0.74 |
| ▸ | GRIN2A | Q12879 | 19/20 | 0.74 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645600 | 0.92 | GRIN1 (0.62) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL16645498 | 0.91 | GRIN1 (0.61) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL16636982 | 0.86 | GRIN1 (0.58) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL16645602 | 0.85 | GRIN1 (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL17958237 | 0.85 | GRIN1 (0.73) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL17958254 | 0.85 | GRIN1 (0.56) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL16637066 | 0.83 | GRIN1 (0.53) | GRIN1GRIN2AGRIA2PDE4APDE4B | |
| SCHEMBL16637862 | 0.76 | GRIN1 (0.85) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL17958086 | 0.76 | GRIN1 (0.84) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL16645491 | 0.76 | GRIN1 (0.70) | GRIN1GRIN2AGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | claimed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | claimed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | claimed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3415519-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052226-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | TPMT, THPO, CYP11B2 | GRIN1 2250/4885GRIN2A 2506/4885GRIA2 2761/4885 |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | GRIN1 2250/4885GRIN2A 2506/4885GRIA2 2761/4885 |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | GRIN1 2250/4885GRIN2A 2506/4885GRIA2 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.